Status:
COMPLETED
Safety and Efficacy of Persistent Atrial Fibrillation Ablation With a Cryoballoon Technology
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-90 years
Brief Summary
The goal of this retrospective observational study is to learn about the safety and efficacy of cryoballoon catheter ablation in 80 patients with persistent atrial fibrillation using the PolarX (Bosto...
Eligibility Criteria
Inclusion
- persistent atrial fibrillation patients undergoing first atrial fibrillation ablation procedure with PolarX cryoballoon
Exclusion
- previous atrial fibrillation ablation or cardiac surgery,
- paroxysmal atrial fibrillation,
- congenital heart disease,
- non-treated coronary artery disease,
- intracavitary thrombus,
- significant valvular disease,
- contraindications to general anesthesia.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06567652
Start Date
January 1 2021
End Date
September 1 2022
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Brussel Heart Rhythm Management Center
Brussels, Belgium, 1090